CytomX Therapeutics
CTMX
68 hedge funds and large institutions have $185M invested in CytomX Therapeutics in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
46.31% more ownership
Funds ownership: 0% → 46.31% (+46%)
10% more funds holding
Funds holding: 62 → 68 (+6)
40% less capital invested
Capital invested by funds: $308M → $185M (-$123M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$11.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.44M |
| 3 |
Renaissance Technologies
New York
|
+$1.1M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.1M |
| 5 |
Morgan Stanley
New York
|
+$715K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$3.89M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$448K |
| 3 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$287K |
| 4 |
Neuberger Berman Group
New York
|
-$224K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$214K |
CTMX Hedge Fund Activity: Q4 2016 in Review
68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2016, worth a combined $185M — down 40% from $308M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CTMX positions and 6 closed out — a net gain of 8 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $11.2M. The largest seller was BlackRock Advisors, cutting an estimated $3.89M.
- 68 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2016, up from 62 in Q3 2016.
- Funds reported $185M of CytomX Therapeutics stock for Q4 2016, down 40% quarter-over-quarter.
- 14 funds opened new CytomX Therapeutics positions in Q4 2016 and 6 closed out, a net change of +8 holders.
- The largest CytomX Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $11.2M added.
- The largest CytomX Therapeutics seller in Q4 2016 was BlackRock Advisors, an estimated $3.89M sold.
Based on aggregated 13F filings for Q4 2016.